A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. (lookformedical.com)
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. (lookformedical.com)
B-cell lymphoid tumors that occur in association with AIDS. (lookformedical.com)
Malignant7
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. (lookformedical.com)
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. (lookformedical.com)
Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. (lookformedical.com)
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. (lookformedical.com)
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. (lookformedical.com)
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. (lookformedical.com)
The malignant cells of LPHD are CD20 + and therefore rituximab may have activity with fewer late effects than standard therapy. (ashpublications.org)
Vitro2
According to in vitro action of mTOR inhibitors in a lot of lym phoma cell lines, the two everolimus and temsiroli mus have finished phase II clinical trials in NHL. (srcinhibitors.com)
2012 Wiley Periodicals, Inc. consecutive consensus conferences, the issues were analyzed and dis- Follicular cell lymphoma (FL) is a frequent disorder for cussed according to the nominal group technique, as previously described [5]. (health-articles.net)
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma : a randomised phase 3 trial. (krakow.pl)
Rituximab12
A new approach that avoids chemotherapy and instead uses a combination of lenalidomide ( Revlimid , Celgene Corporation) plus rituximab ( Rituxan , Genentech, Inc/Biogen Idec Limited) was effective and safe when used as a first-line therapy for mantle cell lymphoma. (medscape.com)
Given that the approach to mantle cell lymphoma treatment is highly variable and decisions are made with consideration of balancing efficacy and toxicity, the lenalidomide plus rituximab regimen represents a useful option to consider for some patients, particularly those who wish to avoid or cannot tolerate more intensive chemotherapy-based treatment," he told Medscape Medical News . (medscape.com)
Lenalidomide, a second-generation immunomodulatory compound, and rituximab, an anti-CD20 antibody, are both active in patients with recurrent mantle cell lymphoma. (medscape.com)
Lenalidomide is approved for use in recurrent mantle cell lymphoma, he explained, and there are good data that suggest that lenalidomide combined with rituximab is more effective than the agent used alone. (medscape.com)
4. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. (nih.gov)
8. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. (nih.gov)
9. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. (nih.gov)
11. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy. (nih.gov)
13. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. (nih.gov)
Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma. (nih.gov)
Bendamustine plus rituximab is effective for relapsed or refractory disease. (nih.gov)
We compared bendamustine plus rituximab with CHOP plus rituximab (R-CHOP) as first-line treatment for patients with indolent and mantle-cell lymphomas. (nih.gov)
DLBCL1
In the 2008 WHO classification, grade 3b FL were separated and are universally treated as diffuse large reported the clinical outcomes in patients in which the ther- B-cell lymphoma (DLBCL) [2]. (health-articles.net)
Therapies1
7. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. (nih.gov)
Recurrent1
Herein, we demonstrate an effective CAR-T cell treatment for recurrent and malignant CD30-positive peripheral T-cell lymphomas (PTCL) has been demonstrated. (bvsalud.org)
Regimens3
We feel that further study of this approach in larger trials will allow a better assessment of its value relative to other mantle cell leukemia regimens. (medscape.com)
A rule of thumb is that patients younger than 65 in the US will most likely receive more intensive regimens and stem cell transplantation, and those that are older, less intensive chemotherapy. (medscape.com)
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. (nih.gov)
Diffuse1
10. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S. (nih.gov)
Medscape1
Fast Five Quiz: Test Your Knowledge of Mantle Cell Lymphoma - Medscape - Jan 09, 2023. (medscape.com)
High-dose chemotherapy2
First-line treatment of mantle cell lymphoma varies, but it generally involves intensive approaches, including high-dose chemotherapy and hematopoietic-cell transplant, note the authors. (medscape.com)
High dose chemotherapy followed by hematopoietic stem cell transplant wasrecommended for young fit patients who achieve a response after salvage chemoimmunotherapy. (health-articles.net)
Leukemia1
New Trials in Leukemia and Lymphoma: Could Your Patient Benefit? (medscape.com)
Patients8
Dr Kahl did note that there is not one standard of care for frontline treatment of mantle cell lymphoma, so it is possible that some physicians may be interested in trying this regimen for certain patients. (medscape.com)
5. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. (nih.gov)
6. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. (nih.gov)
12. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. (nih.gov)
Patients aged 18 years or older with a WHO performance status of 2 or less were eligible if they had newly diagnosed stage III or IV indolent or mantle-cell lymphoma. (nih.gov)
There have been two new PBS listings for lymphoma and Lymphoma Care Nurses are available in Queensland and CLL from 1st September for patients. (lymphoma.org.au)
The nurse learning modules are FREE live webinars that are available to nurses and other health professionals who work with lymphoma/CLL patients. (lymphoma.org.au)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. (krakow.pl)
Outcomes1
2. Burden of illness and outcomes in second-line large B-cell lymphoma treatment: real-world analysis of Medicare beneficiaries. (nih.gov)
Treatment1
1. Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma. (nih.gov)
Chemotherapy1
Although there is no set standard for first-line therapy in mantle cell lymphoma, it usually includes cytotoxic chemotherapy. (medscape.com)
Proliferation2
According to the results of the Cell Count Kit-8 assay, the proliferation of AGS and MKN-45 cells decreased when HKDC1 was knocked down. (bvsalud.org)
As an oncogene in gastric cancer development, HKDC1 influences cell proliferation and glycolysis. (bvsalud.org)
Large1
however, mitoses are more numerous and large cells are infrequent in MCL. (medscape.com)
Study1
This study aimed to construct an integrative score based on various inflammatory and nutritional indexes for prognosis in resectable esophageal squamous cell carcinoma (ESCC). (bvsalud.org)
Generally1
Relapses in mantle cell lymphoma generally occur in the range of 3 to 4 years, Dr Kahl pointed out. (medscape.com)
Zone1
In terms of histologic examination, MCL is characterized by expansion of the mantle zone that surrounds the lymph node germinal centers by small-to-medium atypical lymphocytes . (medscape.com)
Knowledge1
They aim to help nurses to feel more confident in Mater Private Hospital, their knowledge when caring for a lymphoma/CLL patient. (lymphoma.org.au)
Care2
Lymphoma Australia's Nurse News aims to keep nurses with a special interest in lymphoma or CLL up to date with all aspects of lymphoma care local y and from around the world. (lymphoma.org.au)
We thank you for the care that you continue to provide to those affected by lymphoma or CLL. (lymphoma.org.au)
Results1
The results of CD30 CAR T-mediated cell lysis show that 9C11-2 CAR T cells could significantly promote the lysis of CD30-positive Karpas 299 cells in both LDH and real-time cell electronic sensing (RTCA) assays. (bvsalud.org)
Failure1
Male RCS10 mice are characterized by maturity onset obesity, hepatic insulin resistance, beta cell failure, and complete fledged diabetes all over 6 months of age if they are place on the food plan containing 20% calories from fat, The 2nd model studied is B6. (cetp-signal.com)
Protein1
Lack of HKDC1 in cells enhanced oxygen consumption and decreased glycolytic protein expression while suppressing glucose absorption, lactate production, ATP level, and extracellular acidification ratio. (bvsalud.org)